Phage Therapy Market Research Report 2033 | 2026 Baseline, Regional Trends & Leading Manufacturers

Market Snapshot: Key Facts

• 2025 market size: USD 1.2 billion
• 2033 projected size: USD 2.8 billion
• CAGR (2026-2033): 11.4%
• Leading region: Europe
• Fastest-growing region: North America
• Leading application: Antibiotic-resistant bacterial infections
• Fastest-growing application: Chronic wound and cystic fibrosis-related infections
• Dominant end user: Hospitals and specialized infectious disease centers

Introduction

The global phage therapy market was valued at USD 1.2 billion in 2025 and is projected to reach USD 2.8 billion by 2033, growing at a CAGR of 11.4% across the forecast period. Momentum is building as antimicrobial resistance renders an increasing share of bacterial infections untreatable with conventional antibiotics, pushing clinicians and regulators toward bacteriophage-based alternatives with renewed urgency. Compassionate-use approvals for multidrug-resistant infections are generating growing real-world evidence, even as formal regulatory pathways for personalized phage products remain works in progress across most jurisdictions. As the antibiotic pipeline continues to thin, phage therapy is steadily transitioning from experimental last resort toward a more structured clinical option.

Get a free sample report: https://datahorizzonresearch.com/request-sample-pdf/phage-therapy-market-76531

Segmentation: Where Is Demand Concentrated?

By Indication
o Wound and Diabetic Ulcers (42% share 2025; 12.8% CAGR)
o Respiratory Tract Infections (28% share; 10.2% CAGR)
o Urinary Tract Infections (18% share; 9.6% CAGR)
o Systemic and Bloodstream Infections (12% share; 8.4% CAGR)

By Delivery Mode
o Topical and Spray (48% share)
o Inhalation (26% share)
o Oral (16% share)
o Intravenous (10% share)

By Bacterial Target
o Pseudomonas aeruginosa (35% share)
o Acinetobacter baumannii (28% share)
o Staphylococcus aureus (22% share)
o Enterobacteriaceae (15% share)

Regional Insights: Who Is Leading Adoption?

Europe leads the market, anchored by established phage therapy centers in Georgia, Poland, and France, alongside growing EU regulatory engagement on personalized medicine pathways. North America is the fastest-growing region, propelled by FDA compassionate-use approvals, expanding investigator-initiated trials, and rising biotech investment targeting antimicrobial resistance. Asia-Pacific is an emerging growth pocket, with China and India both investing in phage research amid significant domestic antimicrobial resistance burdens. The Middle East and Latin America remain nascent, with activity concentrated in academic research rather than commercial development.

Growth Drivers and Trends

The relentless rise of antimicrobial resistance is the foundational driver, as a shrinking pool of effective antibiotics forces clinicians toward alternative modalities for previously untreatable infections. Growing real-world evidence from compassionate-use cases is building clinical confidence and informing more structured trial designs, gradually de-risking phage therapy for broader institutional adoption. On the regulatory side, agencies in the US and EU are beginning to engage more constructively with the unique challenges personalized phage products pose to traditional drug approval frameworks. A parallel trend is growing biotech investment in engineered and synthetic phage platforms, aiming to improve stability, host-range breadth, and manufacturing scalability beyond naturally sourced phage cocktails.

Top Companies Shaping the Market

1. Adaptive Phage Therapeutics (Gaithersburg, US) develops personalized phage cocktail platforms for multidrug-resistant infections, leveraging rapid phage-matching technology and expanding compassionate-use clinical partnerships.

2. Armata Pharmaceuticals (Marina del Rey, US) focuses on engineered bacteriophage therapeutics for respiratory and other resistant infections, competing through clinical-stage pipeline depth and biotech investor backing.

3. Eligo Bioscience (Paris, France) specializes in CRISPR-armed phage-based therapeutics, differentiating through precision gene-editing delivery technology targeting specific pathogenic bacteria.

4. Phagelux (Montreal, Canada) provides phage-based products spanning therapeutic and agricultural applications, building strength through diversified revenue streams and manufacturing scale.

5. BiomX (Ness Ziona, Israel) develops phage cocktail candidates for chronic infections including cystic fibrosis, positioning itself around targeted pipeline focus and clinical trial partnerships.

Competitive Landscape: How Are Players Differentiating?

Competition centers on phage-matching speed, manufacturing scalability, and regulatory pathway navigation, given the field's unusually close interplay between science and policy. Established biotech players are investing in engineered and synthetic phage platforms to overcome the scalability limits of naturally sourced cocktails, while academic-linked centers compete on clinical expertise and named-patient treatment track records. Partnerships between phage developers and hospital systems are becoming an important channel for generating the real-world evidence needed to support formal regulatory submissions.

Recent Developments Worth Noting

Recent industry activity has generally centered on expanding compassionate-use treatment programs, advancing engineered phage platforms through early clinical trials, and deepening collaborations between phage developers and academic infectious disease centers. Several companies have also been reported to be pursuing formal regulatory pathway discussions with US and European agencies for personalized product frameworks. Readers should consult individual company disclosures for the most current, verified updates.

Outlook: What Should Stakeholders Expect Through 2033?

The phage therapy market is positioned for sustained growth as antimicrobial resistance continues to outpace antibiotic development, creating structural demand for alternative treatment modalities. Companies that combine strong clinical evidence generation with proactive regulatory engagement are best placed to capture share as formal approval pathways mature. North America's accelerating compassionate-use and trial activity is likely to become an increasingly significant driver of global market momentum through the remainder of the decade.

Latest Reports:

AR and VR Market: https://datahorizzonresearch.com/ar-and-vr-market-9229
Flexible Cable for Robots Market: https://datahorizzonresearch.com/flexible-cable-for-robots-market-9905
Connectors for Energy Storage System (ESS) Market: https://datahorizzonresearch.com/connectors-for-energy-storage-system-ess-market-10581
Wheel Barrow Market: https://datahorizzonresearch.com/wheel-barrow-market-11257

Contact Information
Contact Name: Ajay N
Company: DataHorizzon Research
Phone: +1-970-633-3460
Email: sales@datahorizzonresearch.com

About us:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR's comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

This release was published on openPR.